Quarterly ResultMay 7, 2026, 04:20 PM
CAMP4 Files for CMP-002 Clinical Trial; EMA Orphan Designation; Q1 Net Loss $18.3M
AI Summary
CAMP4 Therapeutics reported a net loss of $18.3 million for the first quarter ended March 31, 2026, an increase from $12.4 million in the prior year. The company announced significant clinical progress, including the submission of its first regulatory filing for CMP-002 in Australia and receiving Orphan Designation from the European Medicines Agency. CAMP4 expects to initiate a global Phase 1/2 clinical trial for CMP-002 in SYNGAP1 patients in the second half of 2026 and projects its cash runway into 2028 with $99.2 million in cash and cash equivalents.
Key Highlights
- Submitted first clinical trial regulatory filing for CMP-002 in Australia.
- Received Orphan Designation for CMP-002 by the European Medicines Agency (EMA).
- Anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026.
- Cash and cash equivalents were $99.2 million as of March 31, 2026.
- Cash runway expected into 2028.
- Net loss for Q1 2026 was $18.3 million, compared to $12.4 million in Q1 2025.
- Research and development expenses were $10.2 million for Q1 2026.
- General and administrative expenses were $4.2 million for Q1 2026.